News
OSTX
1.210
-3.20%
-0.040
OS Therapies Announces Warrant Offer to Extend Runway
TipRanks · 10/19 13:24
Weekly Report: what happened at OSTX last week (1012-1016)?
Weekly Report · 10/19 09:42
Weekly Report: what happened at OSTX last week (1005-1009)?
Weekly Report · 10/12 09:45
Herlystic’s Strong Phase 2b Survival Data and Advancing Regulatory Milestones Support Unchanged $6 Price Target and Buy Rating on OSTX
TipRanks · 10/07 16:35
OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma
Benzinga · 10/07 12:40
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
Newsfile · 10/07 12:30
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
Benzinga · 10/06 17:19
OS Therapies Incorporated (OSTX) Receives a Buy from Roth MKM
TipRanks · 10/06 16:35
OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical Control
Benzinga · 10/06 12:40
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Newsfile · 10/06 12:30
OS Therapies bolsters leadership team amid commercialization push
TipRanks · 10/05 21:00
Weekly Report: what happened at OSTX last week (0928-1002)?
Weekly Report · 10/05 09:45
OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO
Seeking Alpha · 10/01 13:01
OS Therapies Appoints Frank Knuettel II As CFO
Benzinga · 10/01 12:34
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Newsfile · 10/01 12:30
Weekly Report: what happened at OSTX last week (0921-0925)?
Weekly Report · 09/28 09:42
OS Therapies: Regulatory Momentum for Herlystic Supports Continued Buy Rating with Unchanged $6 Price Target
TipRanks · 09/25 15:55
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
Newsfile · 09/24 12:22
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Axalta Coating Systems (AXTA)
TipRanks · 09/21 14:30
OS Therapies Provided an Update on Global Early Market Access Regulatory Coordination Efforts By UK's MHRA For OST-HER2 For Pulmonary Metastatic Osteosarcoma Under Project Orbis
Benzinga · 09/21 10:36
More
Webull provides a variety of real-time OSTX stock news. You can receive the latest news about OS THERAPIES INCORPORATED through multiple platforms. This information may help you make smarter investment decisions.
About OSTX
OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.